Cargando…

Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline

Novel antimicrobial agents, approved for clinical use in past years, represent potential treatment options for various infections. In this review, we summarize the most important medical and microbiological features of three recently approved fluoroquinolones, namely delafloxacin, finafloxacin, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kocsis, Béla, Gulyás, Dániel, Szabó, Dóra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698389/ https://www.ncbi.nlm.nih.gov/pubmed/34943718 http://dx.doi.org/10.3390/antibiotics10121506

Ejemplares similares

Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin
por: Kocsis, Bela, et al.
Publicado: (2016)

Investigation of Delafloxacin Resistance in Multidrug-Resistant Escherichia coli Strains and the Detection of E. coli ST43 International High-Risk Clone
por: Gulyás, Dániel, et al.
Publicado: (2023)

In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species
por: Kong, Yingying, et al.
Publicado: (2022)

Profile of a Novel Anionic Fluoroquinolone—Delafloxacin
por: Tulkens, Paul M, et al.
Publicado: (2019)

Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei
por: Barnes, Kay B., et al.
Publicado: (2017)

Diversity and Distribution of Resistance Markers in Pseudomonas aeruginosa International High-Risk Clones
por: Kocsis, Béla, et al.
Publicado: (2021)

Emergence and Dissemination of Extraintestinal Pathogenic High-Risk International Clones of Escherichia coli
por: Kocsis, Béla, et al.
Publicado: (2022)

Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China
por: Kong, Yaoyao, et al.
Publicado: (2023)

In Vitro and In Vivo Activity of Zabofloxacin and Other Fluoroquinolones Against MRSA Isolates from A University Hospital in Egypt
por: MOHAMED, NELLY M., et al.
Publicado: (2019)

Contribution of OqxAB Efflux Pump in Selection of Fluoroquinolone-Resistant Klebsiella pneumoniae
por: Szabo, Orsolya, et al.
Publicado: (2018)

Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
por: Hartley, M. Gill, et al.
Publicado: (2021)

Delafloxacin-Capped Gold Nanoparticles (DFX-AuNPs): An Effective Antibacterial Nano-Formulation of Fluoroquinolone Antibiotic
por: Abu Lila, Amr Selim, et al.
Publicado: (2022)

The Fluoroquinolone Finafloxacin Protects BALB/c Mice Against an Intranasal Infection With Francisella tularensis Strain SchuS4
por: Barnes, Kay B., et al.
Publicado: (2019)

DELAFLOXACIN, A NOVEL FLUOROQUINOLONE ANTIBIOTIC WITH ACTIVITY AGAINST HOSPITAL-, COMMUNITY- AND LIVESTOCK- ASSOCIATED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
por: Maguire, Mollie, et al.
Publicado: (2021)

Simple and Accurate HPTLC-Densitometric Method for Quantification of Delafloxacin (A Novel Fluoroquinolone Antibiotic) in Plasma Samples: Application to Pharmacokinetic Study in Rats
por: Alam, Prawez, et al.
Publicado: (2020)

Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae
por: Park, Hee-Soo, et al.
Publicado: (2016)

Ciprofloxacin-Resistant Pseudomonas aeruginosa Lung Abscess Complicating COVID-19 Treated with the Novel Oral Fluoroquinolone Delafloxacin
por: Panholzer, Jürgen, et al.
Publicado: (2022)

Efficacy of finafloxacin in a murine model of inhalational glanders
por: Barnes, Kay B., et al.
Publicado: (2022)

In Vitro Activity of Finafloxacin against Panels of Respiratory Pathogens
por: Harding, Sarah V., et al.
Publicado: (2023)

Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model
por: Craddock, Vaughn D., et al.
Publicado: (2023)

Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection
por: Barnes, Kay B., et al.
Publicado: (2021)

Delafloxacin: design, development and potential place in therapy
por: Candel, Francisco Javier, et al.
Publicado: (2017)

Updated Review on Clinically-Relevant Properties of Delafloxacin
por: Turban, Adrien, et al.
Publicado: (2023)

2754. Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Demonstration of the Broad-Spectrum In Vitro Activity of Finafloxacin against Pathogens of Biodefense Interest
por: Barnes, Kay B., et al.
Publicado: (2019)

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2020)

Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2017)

Correction to: Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2018)

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties
por: Jorgensen, Sarah C. J., et al.
Publicado: (2018)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone
por: Pfaller, M. A., et al.
Publicado: (2018)

Correction to: Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2021)

Fluoroquinolone antibiotics and adverse events
por: Baggio, Diva, et al.
Publicado: (2021)

Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei
por: McCurdy, Sandra, et al.
Publicado: (2021)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Corey, G Ralph, et al.
Publicado: (2019)

Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones
por: Migliori, Giovanni Battista, et al.
Publicado: (2012)

Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial
por: Rhee, Chin Kook, et al.
Publicado: (2015)

P41 Use of delafloxacin in osteomyelitis: a case report
por: Vidwans, Madhuri, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4if6k2434irh2d9vjg96hcscct